Thermo Fisher Scientific Inc. (NYSE:TMO) is Mirova US LLC’s 7th Largest Position

Mirova US LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 762,525 shares of the medical research company’s stock after selling 23,283 shares during the quarter. Thermo Fisher Scientific makes up approximately 4.8% of Mirova US LLC’s portfolio, making the stock its 7th biggest position. Mirova US LLC owned approximately 0.20% of Thermo Fisher Scientific worth $396,688,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC purchased a new position in Thermo Fisher Scientific during the 3rd quarter worth approximately $26,000. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. FPC Investment Advisory Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $28,000. Pillar Financial Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Finally, Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $519.30 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market capitalization of $195.91 billion, a price-to-earnings ratio of 31.42, a PEG ratio of 2.99 and a beta of 0.79. The company’s 50 day simple moving average is $548.20 and its 200 day simple moving average is $558.14. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific’s payout ratio is presently 10.41%.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wells Fargo & Company upped their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, UBS Group upped their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Four research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average target price of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.